The results revealed that ADCY1 polymorphism rs2293106 (c.3090G>A) was significantly more effective in non-small cell lung cancer patients with platinum-based combined chemotherapy, and the patients with the A allele were more affected than the patients with the G allele who received platinum-based combined chemotherapy [37]. Here, ADCY1 is linked to non-small cell lung carcinoma.